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THE USE of cyclosporine (CyA) has greatly impacted the success of liver transplantation. FK 506 is a 
newly described immunosuppressive agent, with mecha-
nisms of action similar to those of Cy A, but more potent on 
a weight-ta-weight basis. Pilot studies of FK 506 in pri-
mary liver transplantation have shown encouraging re-
sults. 1 A randomized trial using FK 506 with low-dose 
steroids (LDS) was compared to two different Cy A regi-
mens, one with LDS and the other with standard steroid 
therapy (SST). The primary end point was to examine the 
incidence of rejection following liver transplantation, and 
to compare graft and patient survival rates after FK 506 
with LDS, CyA with LDS, and CyA with SST. 
METHODS 
One hundred fifty-four patients were enrolled in a single center 
between February 17, 1990, and Oecember30, 1991. The details of 
randomization, the exclusion criteria, the dosing of FK 506 and 
eyA, and the definition of rejection have been described else-
where.2 LOS therapy consisted of I g of methylprednisolone 
(MP), while SST consisted of I g of MP followed by a 6-day 
steroid taper, for both induction and treatment of rejection. 
RESULTS 
The patient demographics and results are shown in Table 
1. 
A total of 53 (70%) of the patients on CyA were 
converted to FK 506 with LDS immunosuppression, 43 
patients because of recurrent or refractory rejection after 
steroid treatment for rejection. 5 patients for preservation 
injury, 3 patients following retransplantation. I patient for 
Rh incompatibility, and I patient drop-out. Only one 
patient on FK 506 was converted to CyA. Of the patients 
who were converted to FK 506, 22 (42%) of patients are on 
FK 506 only (no steroids), as compared to 41% of patients 
who were randomized to the FK 506 limb initially. 
CONCLUSIONS 
FK 506 with LDS in primary liver transplantation is 
associated with a statistically significant decrease in the 
incidence of rejection. In addition. patient and graft sur-
vival rates are at least the same as. if not better than. after 
CyA-based immunosuppression. CyA with SST appears to 
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Table 1. Patient Demographics and Results 
CyA 
FK WIth WIth 
Parameter 506 Total LOS SST 
Number 78 76 40 36 
Age (y) 43 42 
Diagnosis 
Biliary cirrhosis 13 16 
Hepatocellular carcinoma 65 60 
Median follow-up (days) 611 594 700 402 
Deaths 7 9 7 2 
Retransplants 7 11 8 3 
Rejection free 
Actual (current) 34 7 2 5 
1 Month after 39 16 7 9 
Switch 1 53 32 21 
Steroid tree 32 
have the same rate of development of rejection as com-
pared to CyA with LDS, both of which are lower than FK 
506 with LDS. The side effects, including nephrotoxicity, 
appear to be similar in all three groups. Early reports from 
other centers enrolled in a multicenter randomized trial 
with FK 506 and cyclosporine for liver transplantation 
have noted the efficacy of FK 506, although there exists a 
learning curve for the use of this drug to prevent excessive 
side effects. 
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